Last patient with liver cancer included in the monotherapy part of Medivir's phase Ib study with MIV-818
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study with MIV-818. Like the other patients in the study, the patient is dosed in cycles of three weeks starting with MIV-818 as monotherapy for five days. In parallel, the company is preparing part two of the phase Ib study to be able to begin during the second half of 2021. · It is gratifying that we this far have managed to carry out the study without any major delays despite the ongoing Covid-19 pandemic. We are